20.3 Oral Retinoids & Phototherapy Modalities

20.3 Oral Retinoids & Phototherapy Modalities

Systemic Retinoids in Dermatology

Systemic retinoids are synthetic and naturally occurring Vitamin A derivatives that regulate cell proliferation, epidermal differentiation, sebaceous activity, and immune responsiveness through nuclear receptor interactions.

1. Isotretinoin (13-cis-Retinoic Acid)

• Primary Indications: First-line systemic agent of choice for severe recalcitrant nodulocystic acne, acne conglobata, acne with severe scarring, and acne unresponsive to standard courses of systemic antibiotics combined with topical regimens.
• Molecular Mechanism: Endogenous isomer of all-trans retinoic acid. Binds with low affinity to cytoplasmic retinoic acid-binding proteins and undergoes intracellular isomerization into all-trans retinoic acid. Triggers profound, reversible apoptosis of sebocytes, reducing sebaceous gland size by >90% and slashing sebum excretion rate by 80%–90%. By eliminating the lipid-rich microenvironment, it drastically depletes Cutibacterium acnes populations, normalizes follicular infundibular hyperkeratinization, expels microcomedones, and exerts direct anti-inflammatory activity.
• Dosing & Cumulative Target Dose: Daily dosing ranges from 0.5 to 1.0 mg/kg/day taken with food (a high-fat meal doubles bioavailability of conventional formulations). To achieve long-term definitive clinical remission and minimize post-treatment recurrence, a cumulative dose of 120 to 150 mg/kg over a 16-to-24 week course has traditionally been targeted. Some studies link lower cumulative doses with more relapse, but the evidence is mixed and European guidance increasingly accepts low-dose regimens and treatment to clinical response.
• Teratogenicity & Retinoid Embryopathy: Potent teratogen causing structural malformations in >30% of exposed fetuses during the first trimester. The spectrum of retinoid embryopathy includes:
  • Craniofacial: Microtia, anotia, external auditory canal atresia, microphthalmia, cleft palate, micrognathia.
  • Central Nervous System: Hydrocephalus, microcephaly, cerebellar hypoplasia, cognitive impairment.
  • Cardiovascular: Conotruncal anomalies, transposition of the great vessels, tetralogy of Fallot, aortic arch defects.
  • Thymic: Thymic hypoplasia or aplasia (secondary immune deficiency), parathyroid dysfunction.
• The European Pregnancy Prevention Programme (PPP): Strict regulatory requirements govern prescribing:
  1. Women of childbearing potential must be certified by the prescriber as fully informed regarding teratogenic risk.
  2. Effective Contraception: At least one highly effective, user-independent method (intrauterine device [IUD/IUS] or subdermal implant) or two complementary user-dependent methods (for example a combined oral contraceptive plus a condom), starting 1 month before, continuing throughout treatment, and lasting at least 1 month after stopping.
  3. Supervised Pregnancy Tests: A negative medically supervised pregnancy test before starting, ideally within 3 days before the prescription; repeat tests (ideally monthly) during treatment, and a final test 1 month after stopping.
  4. Prescription Restrictions: Prescriptions are strictly limited to a maximum 30-day supply, and must be dispensed by the pharmacy within 7 days of issuance.
• Mucocutaneous Adverse Effects:
  • Cheilitis: Present in >95%–100% of patients; serves as an objective clinical biomarker of patient compliance and systemic absorption.
  • Xerosis, epistaxis, and dry eyes: Nasal mucosal crusting, contact lens intolerance, blepharoconjunctivitis.
  • Retinoid dermatitis, facial erythema, skin fragility, impaired wound healing (avoid aggressive dermabrasion, laser resurfacing, or waxing for 6 months post-treatment).
  • Telogen effluvium, paronychia, periungual pyogenic granuloma-like lesions, and secondary Staphylococcus aureus skin colonization.
• Laboratory Monitoring:
  • Fasting Lipid Profile: Dose-dependent elevations in triglycerides and total cholesterol. Critical threshold: If serum triglycerides exceed 9 to 10 mmol/L (~800 to 900 mg/dL), therapy must be immediately interrupted or dose reduced due to the acute risk of life-threatening hypertriglyceridemic pancreatitis.
  • Liver Transaminases: Transient ALT/AST elevations occur in up to 15%–20%; discontinue if transaminases exceed 3 times the upper limit of normal (ULN).
  • Complete Blood Count: Rare neutropenia, anemia, or thrombocytopenia.
• Central Nervous System & Drug Interactions:
  • ABSOLUTE CONTRAINDICATION with Tetracyclines: Co-administration with tetracyclines (doxycycline, minocycline, lymecycline) is strictly prohibited due to synergistic elevation of intracranial pressure causing pseudotumour cerebri (idiopathic intracranial hypertension), presenting with severe headache, nausea, projectile vomiting, diplopia (sixth nerve palsy), and papilloedema.
  • Avoid Vitamin A supplements (hypervitaminosis A toxicity).
• Musculoskeletal & Skeletal Effects: Arthralgias and myalgias (exacerbated by vigorous physical exercise, accompanied by elevated creatine kinase [CK]), premature epiphyseal closure in adolescents, and diffuse idiopathic skeletal hyperostosis (DISH-like anterior spinal ligament calcification) with long-term high-dose therapy.
• Neuropsychiatric Controversy: European regulations mandate active patient counseling regarding mood changes, depression, and suicidal ideation at every visit; discontinue therapy if depressive symptoms develop.

2. Acitretin

• Pharmacological Profile: A second-generation mono-aromatic retinoid and the active carboxylic acid metabolite of etretinate.
• Indications: First-line systemic agent for generalized pustular psoriasis (von Zumbusch) and erythrodermic psoriasis; severe plaque psoriasis (often combined with phototherapy: Re-PUVA or Re-UVB); pityriasis rubra pilaris (PRP); severe keratinization disorders (lamellar ichthyosis, Darier disease); and primary chemoprevention of cutaneous squamous cell carcinoma (cSCC) in high-risk solid organ transplant recipients (SOTRs). It is completely ineffective as monotherapy for acne vulgaris.
• Reverse Transesterification & The 3-Year Contraception Mandate:
  • While acitretin has a terminal elimination half-life of ~50 hours, in the presence of ethanol (alcohol ingestion) it undergoes reverse enzymatic transesterification in vivo into ETRETINATE.
  • Etretinate is extraordinarily lipophilic, stores extensively in subcutaneous adipose tissue, and has an enormous terminal half-life of 120 to 168 days (or longer). Trace amounts remain detectable in maternal circulation up to 2 to 3 years post-cessation.
  • Mandatory European Rule: Women of childbearing potential taking acitretin must practice strict dual contraception starting 1 month before, during, and continuing for AT LEAST 3 FULL YEARS AFTER DISCONTINUATION! Alcohol consumption (beverages, foods, medications) is strictly prohibited during and for 2 months after acitretin therapy. Due to this 3-year restriction, acitretin is almost universally avoided in women of reproductive potential.

3. Alitretinoin (9-cis-Retinoic Acid)

• Receptor Selectivity: Endogenous physiological pan-retinoid agonist that binds with high affinity to both nuclear families: RAR (α, β, γ) AND RXR (α, β, γ).
• Licensed Indication: Severe chronic hand eczema (CHE) refractory to potent topical corticosteroids in adults.
• Dosing & Pharmacokinetics: Dosed at 30 mg once daily with a meal (or 10 mg daily in patients experiencing intolerable headaches or mild renal impairment) for 12 to 24 weeks.
• Contraception Duration: Teratogenic (retinoid embryopathy), but has a rapid terminal elimination half-life of 2 to 10 hours. Consequently, mandatory post-treatment contraception is required for ONLY 1 MONTH POST-CESSATION (identical to isotretinoin, completely avoiding the 3-year burden of acitretin).
• Adverse Effects: Fronto-occipital tension-type headache (occurs in up to 30% during the first 1–2 weeks; responds to paracetamol and dose reduction), mucocutaneous xerosis, hypertriglyceridemia, and reversible central hypothyroidism (selective TSH suppression via RXR-mediated inhibition of the TSH-β promoter, producing low free T4 with normal or low TSH without thyroiditis).

---

Phototherapy Modalities: Physics, Mechanisms & Dosing Protocols

Phototherapy utilizes specified non-ionizing optical radiation wavebands to modulate cutaneous immunological and cellular pathways.

Optical Radiation Spectrum Overview

• UVC (200–280 nm): Filtered by atmospheric ozone; germicidal; not used in clinical phototherapy.
• UVB (280–320 nm): High-energy, erythemogenic; absorbed primarily in the epidermis and superficial papillary dermis.
• UVA (320–400 nm): Longer wavelength; penetrates deeply into the reticular dermis and subcutis. Subdivided into UVA-2 (320–340 nm) and UVA-1 (340–400 nm).

Comparative Phototherapy Modalities Table

Detailed Modality Analyses

1. Narrowband UVB (NB-UVB: 311–313 nm)

• Physics & Development: Uses Philips TL-01 fluorescent tubes with an emission peak at 311–313 nm. This narrow spectrum maximizes the therapeutic anti-psoriatic action spectrum identified by Parrish and Jaenicke while eliminating lower, highly erythemogenic wavelengths (<300 nm).
• Immunological Mechanisms:
  1. Induction of cyclobutane pyrimidine dimers (CPD) and 6-4 photoproducts, halting DNA replication.
  2. Triggers p53-dependent apoptosis of epidermal keratinocytes and infiltrating activated T lymphocytes.
  3. Suppresses the IL-23/IL-17 (Th17) and IFN-γ (Th1) cytokine axes while promoting cutaneous secretion of IL-10 and selective expansion of CD4+CD25+FoxP3+ regulatory T cells (Tregs).
  4. Induces depletion and morphological impairment of epidermal Langerhans cells.
  5. In vitiligo, stimulates the proliferation and migration of dormant melanocyte precursors from the hair follicle outer root sheath into the depigmented epidermis.
• Dosing Protocols:
  • MED-Based Protocol (Gold Standard): Determine the Minimal Erythema Dose (MED)—the lowest dose that produces uniform pink erythema at 24 hours. Initiate therapy at 70% of MED.
  • Fitzpatrick Phototype Protocol: Initiate therapy based on skin type (Type I: ~0.13 J/cm², Type II: ~0.22 J/cm², Type III: ~0.30 J/cm²).
  • Treatments are given 2 to 3 times weekly (never on consecutive days) with 10% to 20% dose increments if no erythema occurred after the previous session.
• Oncologic Safety: Large prospective European registries (e.g., Scottish cutaneous phototherapy cohorts) demonstrate no significant increase in squamous cell carcinoma, basal cell carcinoma, or melanoma with standard cumulative courses of NB-UVB monotherapy.

2. Psoralen Plus UVA (PUVA / Photochemotherapy)

• Regimens:
  • Oral PUVA: Oral 8-methoxypsoralen (8-MOP / methoxsalen, 0.6 to 0.8 mg/kg) taken with food 1 to 2 hours prior to UVA irradiation.
  • Bath PUVA: Patient immerses in warm water containing dissolved 8-MOP (0.5 to 2.6 mg/L) for 15 minutes, followed immediately by UVA irradiation (eliminates systemic GI adverse effects and prolonged ocular photosensitivity).
• Molecular Mechanism: Psoralens are planar tricyclic furocoumarins that intercalate between pyrimidine base pairs of double-stranded DNA in the dark. Upon absorption of UVA photons (320–400 nm), 8-MOP forms covalent cyclobutane monoadducts with thymine bases. Absorption of a second UVA photon creates covalent bifunctional interstrand DNA cross-links. These cross-links irreversibly block DNA transcription and replication, triggering profound apoptosis of T lymphocytes, dermal dendritic cells, and mast cells.
• Acute Adverse Effects & Cataract Prevention:
  • Delayed Erythema: PUVA erythema peaks late at 48 to 72 hours post-exposure (unlike UVB which peaks at 12–24 hours).
  • PUVA Itch: Intractable deep cutaneous pruritus.
  • Ocular Phototoxicity: Systemic 8-MOP diffuses into the crystalline lens; ambient UVA exposure binds psoralen to lens proteins, driving cataract formation. Mandatory Rule: Patients must wear UVA-blocking wrap-around sunglasses during irradiation and whenever exposed to sunlight for 24 hours post-ingestion.
• Severe Photocarcinogenesis (The Cumulative Lifetime Threshold):
  • PUVA induces permanent, mutagenic DNA transversion mutations.
  • Patients receiving >150 to 200 cumulative lifetime PUVA sessions experience an exponential >10- to 30-fold increased risk of cutaneous squamous cell carcinoma (cSCC), frequently presenting as aggressive, multiple, metastatic tumors on non-sun-exposed skin (e.g., male genitalia, buttocks).
  • A large US cohort (Stern) found an increased melanoma risk after a latency of about 15 years in heavily treated patients; European cohorts have not consistently confirmed this.
  • European Practice Mandate: Strict cumulative lifetime ceiling of ≤150 to 200 PUVA treatments; mandatory opaque genital shielding during every session; and lifelong full-body skin cancer surveillance.

3. UVA-1 Phototherapy (340–400 nm)

• Physics & Penetration Depth: Isolates long-wave UVA-1 (340–400 nm), filtering out erythemogenic UVB and short-wave UVA-2 (320–340 nm). Its longer wavelength achieves deep penetration through the epidermis and papillary dermis into the reticular dermis and upper subcutaneous tissue.
• Biological Mechanisms:
  1. Generates reactive oxygen species, predominantly singlet oxygen ($^{1}\text{O}_2$).
  2. Triggers profound upregulation of matrix metalloproteinase-1 (MMP-1 / interstitial collagenase) and MMP-3 in dermal fibroblasts, breaking down excess accumulated collagen bundles.
  3. Downregulates pro-fibrotic TGF-β and suppresses type I and type III collagen synthesis.
  4. Induces immediate and delayed apoptosis of pre-activated dermal T lymphocytes and mast cells via p53-independent CD95 (Fas/APO-1) pathways.
• Primary Indications: Sclerotic skin disorders: localized scleroderma (morphoea / morphea), systemic sclerosis, sclerotic chronic graft-versus-host disease (cGvHD), and eosinophilic fasciitis (Shulman syndrome). Also highly effective for acute severe flares of atopic dermatitis and cutaneous mastocytosis.